Introduction
============

Naa10, the *N*-alpha-acetyltransferase 10, is the catalytic subunit of the *N*-alpha-acetyltransferase protein complex NatA. The *NAA10* gene lies in the gene-rich region Xq28 and is composed of 8 exons (NM_003491.3; [Figure 1a](#fig1){ref-type="fig"}). It is highly expressed in the developing brain of mice embryos^[@bib1]^ and shows a lower yet uniform and ubiquitous expression in adult mice.^[@bib2]^ Complete knockout is lethal in *Trypanosoma brucei*,^[@bib3]^ *Caenorhabditis elegans*^[@bib4]^ and *Drosophila melanogaster*.^[@bib5]^ The N-terminal two-thirds of the encoded protein show a globular conformation and contain a dimerization and the catalytic N-acetyltransferase domains, while the C-terminal third represents an unstructured flexible tail.^[@bib6]^ By dimerization of Naa10 with the auxiliary subunit Naa15, the major *N*-acetyltransferase complex in eukaryotes -- NatA -- is formed.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10]^ This complex is not only responsible for acetylation of nascent polypeptides at the ribosomes^[@bib11]^ but also shows non-ribosomal localization^[@bib12]^ and posttranslational acetylation activity.^[@bib13]^ The acetyl-coenzyme-A dependent *N*-alpha-acetylation is the most common protein modification with approximately 80--90% of all proteins in humans being modified by the NAT enzyme complexes (NatA-F),^[@bib14]^ which differ in substrate specificity and subunit composition.^[@bib15]^ For a long time, *NAA10* has been studied as a cancer candidate gene,^[@bib16],\ [@bib17],\ [@bib18]^ and it has been suggested to have a role in enzymatic and non-enzymatic regulation of dendrite growth,^[@bib19]^ cell cycle control and apoptosis induction.^[@bib20]^ This large number of cellular functions and the lethality in knockout model organisms is in accordance with the severe phenotype previously described in Ogden syndrome patients (MIM 300855). Rope *et al*^[@bib21]^ described this new syndrome as a rare lethal X-linked disorder of infancy. Strikingly, the eight affected boys from two independent families showed the exact same inherited c.109T\>C p.(Ser37Pro) variant in hemizygous state leading to a highly recognizable phenotype (see [Table 1](#tbl1){ref-type="table"}). The serine codon affected by this variant lies in exon 2 of the *NAA10* gene within the dimerization domain with Naa15 and is highly conserved in eukaryotes.^[@bib22],\ [@bib23]^

Recently, exome sequencing has been successfully applied in large studies to identify *de novo* mutations in cases of intellectual disability.^[@bib24],\ [@bib25]^ However, these studies mostly replicated known disease-associated genes. Due to the heterogeneity of the identified mutations, the authors could only imply previously not associated genes as causative based on *de novo* truncating mutations. As the *de novo* criterion, even in combination with a second mutation, is not sufficient to reach exome-wide significance and thus to establish pathogenicity, further replication studies in individuals with a similar phenotype and functional analysis of the new candidate genes are required.^[@bib26],\ [@bib27]^

Using exome sequencing in singleton trios, we identified two different *de novo* missense variants in the *NAA10* gene in two unrelated patients, a girl and a boy, with severe but unspecific global developmental delay. Functional analyses of the novel as well as the previously published variants support causality and suggest a genotype--phenotype correlation.

Materials and methods
=====================

Clinical data
-------------

This study was approved by the ethics committee of the Medical Faculty, Universität Erlangen-Nürnberg, and by the Kantonale Ethikkommission Zurich, and written consent was obtained from parents or guardians of the patients.

Family A
--------

The first patient (Individual II-3 of family A) was a girl aged 2 years and 11 months at the last investigation. She was born with normal birth weight and length, after an uneventful pregnancy as the third child of healthy non-consanguineous parents of German descent. As an infant, she had feeding problems and recurrent infections. She developed postnatal short stature with microcephaly. At the last physical examination, she had a height of 81 cm (−4.38 SD), a head circumference of 45.7 cm (−3.04 SD) and a weight of 10.3 kg. Her developmental course showed severe intellectual disability without regression. She could sit at age 2 years but does not walk or speak, so far. The girl has only minor unspecific dysmorphic features, the most obvious being long curved eyelashes, thin arched eyebrows, a broad nasal bridge and a thin arched upper lip. She showed distinct skeletal anomalies like delayed closure of the fontanels (age 2 years 1 month), a delayed bone age (1 year 6 months at age 2 years 9 months) and also broad great toes and a mild pectus carinatum. The girl was a floppy infant with initial hypotonia progressing to hypertonia of the extremities and truncal hypotonia later in life. Sonography of the brain showed borderline normal ventricles at 8 months of age. An MRI could not be performed due to respiratory arrest under propofol sedation. The patient shows stereotypic behaviours, such as self-hugging and repetitive hand movements. She also shows only little eye contact. As an infant, the girl had a systolic murmur, which led to identification of a pulmonary artery stenosis and an atrial septal defect. At 4 years and 8 months of age, her mother reported that a prolonged QT interval was identified by electrocardiography. No molecular testing has been performed, and there is no familial history for long QT-syndrome.

Standard karyotyping and genetic testing for Prader Willi, Angelman and Noonan syndromes, as well as sequencing of *MECP2*, *TCF4* and *CDKL5* were unremarkable as was a high-resolution chromosomal microarray analysis (CMA). The X-inactivation pattern was random.

Family B
--------

The second patient (Individual II-1 of family B) was a boy aged 10 years 7 months, who was 5 years 11 months at the last physical examination. He was born with normal birth weight and length as the first child of healthy non-consanguineous parents of Swiss descent. Like the girl, this boy also developed postnatal growth retardation but to a lesser extent. At the time of investigation, he was 108 cm tall (−1.83 SD), had a head circumference of 50 cm (−1.68 SD) and a weight of 18 kg. He reached a social smile at age 6 months, could sit at age 18 months, started to walk independently at the age of about 6 years but did not develop speech or bowel or bladder control. Auto-aggressive behaviour with hand biting was a transient problem. He was able to drive a tree wheeler, was shy and hyperactive and needed constant supervision. Formal testing at the age of about 8 years showed severe intellectual disability with a developmental age of about 12 months and autistic features. He had minor unspecific dysmorphic facial features, such as a prominent forehead, deep-set eyes with long eyelashes, down slanting palpebral fissures and rather big ears. Also he had a high arched palate, wide interdental spaces and very small hands and feet. He had truncal hypotonia with hypertonia of the extremities.

Brain imaging through sonography showed enlarged ventricles and MRI scanning at the age of 5 years and 6 months revealed reduced periventricular volume and gliotic changes. Electroencephalography under photic stimulation showed generalized epileptiform activity.

Previous genetic testing for Angelman and Fragile X syndromes were unremarkable as was a high-resolution CMA. The healthy mother had a normal non-skewed X-inactivation.

Exome sequencing
----------------

For family A, enrichment for whole-exome sequencing was performed on DNA from individual II-3 and her parents using the SureSelect Human All Exon Kit V3 (50 Mb, ∼21000 genes) (Agilent Technologies, Santa Clara, CA, USA). Post-hybridization barcodes were used to allow multiplexing (Agilent Technologies). The Beckman Coulter SPRIworks (Beckman Coulter, Danvers, MA, USA) platform was used for the automated library preparation. Sequencing was carried out with 50 bp single reads on a SOLiD 4 system (Life Technologies, Carlsbad, CA, USA). On average, we obtained \>125 million reads per individual. Read alignment to the hg19 reference genome was performed with the novoalignCS software V1.03.03 (NovoCraft Technologies, Petaling Jaya, Malaysia) and yielded approximately 80 million aligned reads on target per individual. The mean target coverage was 48, while 71 % of the target sequence was covered at least five times. Variant calling was performed using GATK UnifiedGenotyper v2.7 after removing duplicate reads, local realignment of indels and base-quality-score recalibration.^[@bib28],\ [@bib29]^ For the index patient, a total of 47385 SNVs and 4612 Indels were annotated using ANNOVAR.^[@bib30]^ After applying filtering and manual inspection using the IGV browser^[@bib31]^ only 1 potential *de novo* variant remained and was validated by Sanger sequencing (see [Supplementary Table S2](#sup1){ref-type="supplementary-material"}) in the patient and her parents. Paternity was confirmed using identity by state calculation with PLINK.^[@bib32]^

The second patient was identified in an exome sequencing study of 51 patients with non-specific severe ID using an Illumina HiSeq2000 platform and has been briefly reported by Rauch *et al*^[@bib24]^ Details on exome sequencing are described there.

The identified *de novo* variants were submitted to ClinVar (accessions SCV000154970 and SCV000154971) and to the LOVD gene variant database at <http://www.lovd.nl/NAA10> (individual IDs 16948 and 16949).

Sanger sequencing
-----------------

Genomic DNA was isolated from blood lymphocytes according to standard procedures. *De novo* variants were confirmed by PCR and bidirectional sequencing using the subjects\' original DNA samples. The DNA samples were then screened for other *NAA10* variants by bidirectional sequencing of all *NAA10* exons (1--8; numbered after NM_003491.3), including flanking intronic regions. PCR amplification and Sanger sequencing were performed as previously described.^[@bib33]^ Primer sequences (see [Supplementary Table S3](#sup1){ref-type="supplementary-material"}) were determined using the Exon Primer program from the UCSC genome browser,^[@bib34]^ and primers were supplied by Thermo Fisher Scientific (Ulm, Germany).

*In silico* analysis and 3D homology modeling
---------------------------------------------

Prediction of potential deleterious effects of missense variants detected in *NAA10* was performed using the software tools SIFT,^[@bib35]^ PolyPhen2,^[@bib36]^ SNAP^[@bib37]^ and PANTHER^[@bib38]^ (see [Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Both novel variants in Naa10 are located in the acetyltransferase domain, which was modeled using the structure of the homologous ARD1 domain from *Sulfolobus* as template (PDB code: 2X7B).^[@bib39]^ Modeling of the wild-type (WT) proteins was performed using SwissModel.^[@bib40]^ Variants were introduced in the structure by selecting the lowest-energy sidechain rotamer of the mutated residue. Energy minimization was performed using Sybyl7.3 (Tripos International, St Louis, MO, USA), and RasMol^[@bib41]^ was used for structure analysis and visualization.

The WT and mutant proteins are shown in Figure 3, and the interpretation of their effect is given in the legend of the figure.

Functional analysis of the Naa10 variants
-----------------------------------------

In order to examine the effects of the two variants on the catalytic activity of hNaa10, quantitative Nt-acetylation assays were performed. We analysed the catalytic activity of the two variants p.(Val107Phe) and p.(Arg116Trp) and compared the activity with Naa10 WT and the previously described p.(Ser37Pro) variant causing Ogden syndrome (Figure 4). The substrate peptides tested included a classical co-translational NatA substrate high-mobility group protein A1 with the N-terminus SESS,^[@bib14]^ and two posttranslational Naa10 targets, EEEI and DDDI, representing the N-termini of *γ*-actin and *β*-actin, respectively.^[@bib12]^

Plasmid construction and protein purification
---------------------------------------------

Plasmids encoding MBP-Naa10 p.(Arg116Trp) and MBP-Naa10 p.(Val107Phe) were created by site-directed mutagenesis (QuikChange Multi Site-Directed Mutagenesis kit, Agilent Technologies) according to the manufacturer\'s protocol. A pETM41 vector (G. Stier, EMBL, Heidelberg, Germany) encoding Naa10 WT with Maltose Binding Protein/His-fusion as a fusion tag was used as a template for the site-directed mutagenesis.^[@bib12]^ Primers used for the mutagenesis were h*NAA10* G319T f: 5′-CTTCAATGCCAAATATTTCTCCCTGCATGTCAGG-3′ and h*NAA10* C346T f: 5′-GTCAGGAAGAGTAACTGGGCCGCCCTG-3′. Mutations were verified by Sanger sequencing and transformed into *E. coli* BL21 Star (DE3) by heat-shock transformation for protein expression. *E. coli* BL21 cells were grown in 200 ml cell cultures to an OD 600 nm, cultures were cooled down to 16 °C and protein expression was started by the addition of IPTG to a total concentration of 500 *μ*M. After 14 h of incubation, cell cultures were harvested, and the pellet was stored on −20 °C. Pellets were dissolved in lysis buffer (50 m[M]{.smallcaps} Tris-HCl (pH 7,4), 300 m[M]{.smallcaps} NaCl, 2 m[M]{.smallcaps} DTT, 50 m[M]{.smallcaps} L-arginine, 50 m[M]{.smallcaps} L-glutamic acid and one tablet of EDTA-free protease inhibitor pr 50 ml), and cells were lysed by 6 × 60 s of short-pulse sonication on ice. Recombinant MBP-hNaa10 was purified by Immobilized Affinity Chromatography (HisTrap HP, GE Healthcare, Buckinghamshire, UK) and Size Exlusion Chromatography (Superdex 200 10/300, GE Healthcare). Buffers used for purification were: IMAC wash buffer (50 m[M]{.smallcaps} Tris-HCl (pH 7.4), 300 m[M]{.smallcaps} NaCl, 2 m[M]{.smallcaps} DTT, 50 m[M]{.smallcaps} L-arginine, 50 m[M]{.smallcaps} L-glutamic acid, 20 m[M]{.smallcaps} imidazole), IMAC elution buffer (50 m[M]{.smallcaps} Tris-HCl (pH 7.4), 300 m[M]{.smallcaps} NaCl, 2 m[M]{.smallcaps} DTT, 50 m[M]{.smallcaps} L-arginine, 50 m[M]{.smallcaps} L-glutamic acid, 300 m[M]{.smallcaps} imidazole) and Size Exclusion Chromatography buffer (50 m[M]{.smallcaps} Tris-HCl (pH 7.4), 300 m[M]{.smallcaps} NaCl, 2 m[M]{.smallcaps} DTT, 50 m[M]{.smallcaps} L-arginine, 50 m[M]{.smallcaps} L-glutamic acid). Fractions were analysed by SDS-PAGE, and protein concentration was determined by both A280 measurements (Nanodrop1000, Thermo Fisher Scientific, Wilmington, DE, USA) and Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA).

Quantitative *in vitro* acetylation assay
-----------------------------------------

Purified recombinant MBP-hNaa10 was mixed with acetyl-CoA (600 m[M]{.smallcaps}), synthetic oligopeptides (300 m[M]{.smallcaps}) and acetylation buffer (50 m[M]{.smallcaps} Tris-HCl (pH 8.5), 1 m[M]{.smallcaps} EDTA, 10% glycerol), incubated at 37 °C and stopped after 10, 20 and 30 min by adding 10% trifluoroacetic acid (TFA). Product formation was quantified with RP-HPLC as described previously.^[@bib42]^ In the quantitative acetylation assay, the following oligopeptides (Biogenes, Berlin, Germany) were used: EEEI (\[H\]EEEIAAL RWGRPVGRRRRPVRVYP\[OH\]) representing *γ*-actin, DDDI (\[H\]DDDIAAL RWGRPVGRRRRPVRVYP\[OH\]) representing *β*-actin and SESS (\[H\]SESSSKS RWGRPVGRRRRPVRVYP\[OH\]), representing high-mobility group protein A1.

Results
=======

Previously, we described a probable disease-causing hemizygous *de novo* missense variant c.346C\>T p.(Arg116Trp) in *NAA10* in a boy (individual II-1 from family B) with severe developmental delay.^[@bib24]^ Using exome sequencing, we now identified a further heterozygous *de novo* variant c.319G\>T p.(Val107Phe) in a girl (individual II-3 from family A) presenting with severe global developmental delay ([Figures 1a--c](#fig1){ref-type="fig"}). Both individuals described here show severe global developmental delay, growth retardation and some overlapping features as summarized in [Table 1](#tbl1){ref-type="table"} (see also [Figure 2](#fig2){ref-type="fig"}).

Both variants were neither listed in dbSNP (build 137)^[@bib43]^ nor in NHLBI Exome Sequencing Project (ESP; EVS-v.0.0.22, Oct. 17, 2013)^[@bib44]^ database or the 1000 Genomes Project (release April 2012)^[@bib45]^ and absent from in-house controls (c.319G\>T: 434 SOLiD exomes; c.346C\>T: 939 Illumina exomes). The *de novo* status was confirmed by Sanger sequencing in both cases. Additional Sanger sequencing of all coding exons showed no second variant in the girl.

Individual II-1 of family B also had two other *de novo* missense variants, namely in the *KRT27* gene c.877G\>C p.(Asp293His) and in the *MYO1E* gene c.1468G\>A p.(Gly490Arg).^[@bib24]^ These two variants were excluded as causative for the phenotype seen in this boy (see [Supplementary Table S4](#sup1){ref-type="supplementary-material"} and discussion there).

The two identified *de novo* missense variants in the catalytic *N*-acetyltransferase domain of Naa10 affect highly conserved amino-acid residues both in orthologous and paralogous genes ([Figure 1a, d and e](#fig1){ref-type="fig"}). As *in silico* predictions using different algorithms classified both variants between benign and deleterious ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}), we further studied them using 3D homology modelling. These protein structure-based predictions revealed that the Trp116 mutation most probably hampers CoA binding and reduces the enzymatic activity of Naa10, while the bulky mutant Phe107 side chain does not fit in the hydrophobic core of the protein and therefore might reduce protein stability or enzymatic activity of the protein ([Figure 3](#fig3){ref-type="fig"}).

We next performed *in vitro* analysis of the mutant proteins through N-terminal acetylation assays with WT, both mutant proteins and the previously described missense variant to elucidate reduced catalytic activity as pathogenic mechanism. Of all the three known, presumably pathogenic missense variants, p.(Val107Phe) has the strongest reduction in activity and is almost catalytically dead (∼95% reduction in the catalytic activity) towards all three tested oligopeptides in comparison with Naa10 WT ([Figure 4](#fig4){ref-type="fig"}). The Naa10 p.(Arg116Trp) variant seen in the boy (Individual II-1 of family B) in contrast has a small but significant reduction in the catalytic activity for the oligopeptides EEEI and SESS (∼15% reduction in the catalytic activity) in comparison to Naa10 WT. This small effect greatly differs from the effects seen for the p.(Ser37Pro) variant, which has a reduction of catalytic activity ranging from 30 to 70% dependent of the substrate oligopeptide.

Discussion
==========

We report two novel *de novo* missense variants in the *NAA10* gene, c.319G\>T p.(Val107Phe) and c.346C\>T p.(Arg116Trp) in two patients with severe global developmental. We show that both variants significantly reduce the catalytic activity of the *NAA10* gene product, an enzyme involved in N-terminal acetylation of proteins.

The two individuals described here, carrying *de novo* missense variants in the *N*-acetyltransferase domain, show a milder non-lethal phenotype without striking dysmorphic features, more similar to one another than to the cases described previously.^[@bib21],\ [@bib46]^ Although the most noticeable overlap in all patients with probably pathogenic variants in *NAA10* is severe global developmental delay with postnatal growth failure and skeletal anomalies, individual II-3 of family A and individual II-1 of family B moreover share behavioural anomalies, truncal hypotonia with hypertonia of the extremities and some minor facial features ([Table 1](#tbl1){ref-type="table"}).

While this manuscript was in preparation, Esmailpour *et al*^[@bib46]^ reported the identification of a splice-donor variant (c.471+2T\>A) in the *NAA10* gene in a family^[@bib47]^ with Lenz microphthalmia syndrome. This variant resulted in no detectable normal *NAA10* gene products but in different aberrant transcripts and low expression of a truncated protein.^[@bib46]^ The four affected males described had congenital bilateral anophthalmia, postnatal growth failure, skeletal anomalies, hypotonia and moderate-to-severe mental retardation with a high degree of intra-familial variation.^[@bib47]^ The authors also describe three heterozygous carrier females having mild symptoms with abnormally shaped ears, syndactyly of the toes, short terminal phalanges and short stature.^[@bib47]^

All the affected boys in the two families reported by Rope *et al.*^[@bib21]^ showed severe postnatal growth delay, severe developmental delay and some dysmorphic features. Also there were skeletal anomalies, structural anomalies of the heart and arrhythmias in electrocardiography. Death in all boys occurred between 5 and 16 months of age and was associated with cardiogenic shock or severe infection. Where performed, autopsy showed cerebral atrophy.^[@bib21]^

Though Rope *et al*^[@bib21]^ conducted *in vitro* acetylation assays and could show a 40--80% reduction in enzymatic activity for the mutant protein expressed in their patients, the underlying disease mechanism was not elucidated.^[@bib21]^ To compare the remaining catalytic activity and thereby the severity of our two *de novo* variants, we performed N-terminal acetylation assays using all three missense variants described above. Despite only a small number of likely pathogenic distinct variants and uncertainty whether the *in vitro* results reflect the *in vivo* situation, our data implies a correlation between remaining catalytic activity of the particular *NAA10* variant and the severity of the phenotype observed in each patient.

First, the high remaining activity of the p.(Arg116Trp) variant helps explain the relatively mild phenotype seen in the male patient when compared with the previously known males with Ogden syndrome ([Figure 4](#fig4){ref-type="fig"}). In males, no deletions spanning the *NAA10* gene are known, although deletions upstream (*MECP2*) and downstream (*L1CAM*) of the gene are documented and cause distinct syndromes (MIM 300673 and MIM 303350) in males.^[@bib48],\ [@bib49]^ Thus, in accordance with the observed lethality of homozygous knockout in model organisms a complete loss-of-function of *NAA10* seems to be lethal in hemizygous males. Altogether, as only hypomorphic mutations are present in males, it seems that more severe mutations, such as the p.(Val107Phe) variant, in hemizygous state might lead to an early intrauterine fetal death, which escapes analytical capabilities. This is further strengthened by the carrier mothers described by Esmailpour *et al.*^[@bib46]^ having multiple spontaneous abortions.

The almost abolished catalytic activity for the p.(Val107Phe) variant seen in the girl could also account for her phenotype through a dominant-negative effect. This assumption is based on heterozygous female carriers previously being described as healthy and also large deletions encompassing the *NAA10* gene being documented in the DECIPHER^[@bib50]^ database in females with intellectual disability as phenotype when reported. The absence of deletions spanning the *NAA10* gene in controls according to the Database of Genomic Variants^[@bib51]^ can either point to the assumption that heterozygous loss-of-function in females is pathogenic or more likely that this relatively gene-dense region shows a low activity for genomic rearrangements. Consequently, as we excluded recessive inheritance to a great extent in the girl, an X-linked dominant mode of inheritance seems causative, either through a dominant-negative effect of the altered Naa10 protein in the NatA complex or a mixture of loss-of-function and dominant-negative effects. Although we excluded skewing of X-inactivation in blood, the phenotypic gap between the girl described here and the mothers of the Ogden families could also be explained by skewed X-inactivation in the nervous system. Indeed Esmailpour *et al*^[@bib46]^ discussed the possibility of X-chromosome skewing for the mild manifestations in the heterozygous females carrying the c.471+2T\>A splice-mutation. Also the variable expression and severity of clinical symptoms could be explained by yet unknown genetic modifiers (eg, variants in other NAT complex genes) or simply because missense mutations can have very diverse effects on the protein function.^[@bib52]^ An example of another X-linked dominant disease showing a high phenotypic variability in female carriers is the Coffin-Lowry syndrome (MIM 303600); depending on the severity of the mutation in the *RSK2* gene, females either have only minor manifestations or develop the full phenotype with facial dysmorphism, tapering fingers and skeletal deformities.^[@bib53],\ [@bib54]^

Although the inherited p.(Ser37Pro) variant lies close to the N-terminus in the dimerization domain and the c.471+2T\>A variant leads to the truncation of the unstructured C-terminus, both *de novo NAA10* variants lie in close proximity in the catalytic *N*-acetyltransferase domain. Taking into account the diverse cellular functions of the NatA complex, it is likely that these four variants show a different alteration in the NatA complex function. As a result, the affected boys in the two families described by Rope *et al*^[@bib21]^ carrying the exact same missense mutation show a strikingly similar phenotype and the affected males in the family described by Esmailpour *et al*^[@bib46]^ also show a comparable phenotype while the two patients described here have a more diverse phenotype.

For the first described pathogenic variant in *NAA10*, p.(Ser37Pro), Rope *et al*^[@bib21]^ could show a hampered NatA activity towards synthetic peptides. For the newly described splice variant, the authors did not analyse the catalytic activity of the truncated protein but discussed that the absent expression of WT Naa10 and only minimal expression of mutant Naa10 would lead to reduced activity of the NatA complex in the patients\' cells.^[@bib46]^ Our results imply that reduced catalytic activity of the NatA complex is pathogenic. Still, as this complex acetylates about 38% of all human proteins,^[@bib15]^ the downstream targets and molecular mechanisms *in vivo* remain unclear and other functions of Naa10 could influence the phenotype. Actually, Esmailpour *et al.*^[@bib46]^ could show a loss of TSC2 interaction^[@bib46]^ for the truncated Naa10 protein, and a recent study by Van Damme *et al*^[@bib22]^ could prove a reduced NatA complex formation *in vivo* for the p.(Ser37Pro) variant. Further functional studies may provide more insight into the underlying pathogenic mechanism.

In conclusion, we have identified two *de novo* variants in *NAA10* in two unrelated individuals Also we describe the first affected female, with severe global developmental delay and a *de novo* variant in *NAA10*. Identification of more individuals carrying new variants in *NAA10* is needed to fully characterize the full phenotypic spectrum associated with N-terminal-acetyltransferase deficiency.

Finally, our study adds to the growing evidence that current syndrome descriptions are incomplete and strongly biased by phenotypic grouping in small-scale study. Thus unbiased large-scale sequencing approaches are needed to fully understand the complex relation between genotype and phenotype in human developmental diseases.^[@bib24],\ [@bib25]^
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![(**a**) Genomic position and domain structure of the *NAA10* gene with positions of the herein described *de novo* variants (Exon 5/6) and the previously reported Ogden syndrome variant (Exon 2). Exons are numbered after NM_003491.3. The domain structure is based on the NCBI reference sequence NP_003482 and the recently described crystal structure of the NatA complex.^[@bib23]^ (**b**, **c**) Pedigrees of the two singleton families and results of Sanger validation. (**d**) Amino-acid sequence alignment of Naa10 orthologs at the *de novo* variant positions shows high sequence conservation. (**e**) Amino-acid sequence alignment of Naa10 and known human NATs shows conservation of the *N*-acetyltransferase domain part containing the *de novo* variants. Protein sequences were obtained from the UCSC Genome Browser,^[@bib34]^ and T-Coffee^[@bib55]^ was used for alignment.](ejhg2014150f1){#fig1}

![(**a**) Individual II-3 of family A at age 2 years and 11 months. (**b**) Individual II-1 of family B at age 5 years and 11 months; only minor dysmorphisms and no syndromic features were observed.](ejhg2014150f2){#fig2}

![Structural effects of the p.(Val107Phe) and p.(Arg116Trp) variants in the acetyltransferase domain of Naa10 (cyan ribbon). The cofactor coenzyme A (CoA) is shown in space-filled presentation and coloured according to the atom type. The variant site is shown in green and key interacting residues in magenta. (**a**) Val107 is located in the hydrophobic core of the enzyme and tightly interacts with other hydrophobic residues, such as Met98. (**b**) Phe107 cannot be accommodated in the hydrophobic core due to its larger side chain and forms steric clashes with adjacent residues (denoted by a red arrow). These clashes are expected to cause protein unfolding and loss of enzymatic activity. (**c**) Arg116 is located close to the cofactor coenzyme A (CoA). (**d**) Trp116 preferentially adopts a side chain orientation that interferes with CoA binding. The steric clashes between Trp116 and CoA are indicated by a red arrow. These clashes are expected to hamper CoA binding and to reduce the enzymatic activity.](ejhg2014150f3){#fig3}

![*In vitro* N-terminal acetyltransferase activity of Naa10 variants. Purified recombinant hNaa10 WT and mutants were mixed with 300 m[M]{.smallcaps} oligopeptide and 600 m[M]{.smallcaps} acetyl-CoA and incubated at 37 °C. (**a**) Time-dependent acetylation of the oligopeptide EEEI by purified recombinant hNaa10 WT, hNaa10 p.(Arg116Trp), hNaa10 p.(Val107Phe) and hNaa10 p.(Ser37Pro). The reaction was stopped at different time points by the addition of 10% TFA. (**b**) NAT activity of hNaa10 WT and hNaa10 mutants towards substrate oligopeptides EEEI, DDDI and SESS. Bars are showing product formation in (or close to) the linear phase of the reaction, after 10 min of incubation. Measurements statistically significant from hNaa10 WT by independent two-tailed *t*-tests are indicated with an asterisk (*P*\<0.05).](ejhg2014150f4){#fig4}

###### Features of all individuals with *NAA10* mutations

                                                       *Rope et al*^[@bib21]^(n*=8)*                                                                                                                  *Esmailpour et al*^[@bib46]^/*Forrester et al*^[@bib47]^ (n*=4)*                                                                                  *Family B Individual II-1*                                                                                   *Family A Individual II-3*
  ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------
  Variant (NM_003491.3)                                c.109T\>C p.(Ser37Pro)                                                                                                                         c.471+2T\>A (p.Glu157fs45\* p.0?)                                                                                                                 c.346C\>T p.(Arg116Trp)                                                                                      c.319G\>T p.(Val107Phe)
  Inheritance                                          Inherited                                                                                                                                      Inherited                                                                                                                                         *De novo*                                                                                                    *De novo*
  Gender                                               Male (8/8)                                                                                                                                     Male (4/4)                                                                                                                                        Male                                                                                                         Female
  Age at last follow-up examination (\*age of death)   5--16 months\*                                                                                                                                 14--28 years                                                                                                                                      5 years 11 months                                                                                            2 years 11 months
  Postnatal growth failure                             8/8                                                                                                                                            4/4                                                                                                                                               Yes                                                                                                          Yes
  Developmental delay                                  Severe (8/8)                                                                                                                                   Severe (3/4), mild (1/4)                                                                                                                          Severe                                                                                                       Severe
  Facial                                               Large ears (6/8), down slanting palpebral fissures (4/8), prominent eyes (4/8), flared nares (3/8), hypertelorism (3/8), long philtrum (3/8)   Large abnormally formed ears (4/4), abnormally developed eyes (4/4), prominent philtrum (3/4)                                                     Prominent forehead, deep set eyes, long eyelashes, down slanting palpebral fissures, large ears, diasthema   Long curved eyelashes, thin arched eyebrows, broad nasal bridge, thin arched upper lip
  Skeletal                                             Large fontanels (5/8), broad or widely spaced toes (2/8), delayed osseous development (1/8)                                                    High arched palate (4/4), clinodactyly (4/4), syndactyly (4/4), scoliosis (3/4), pectus excavatum (3/4), pes planus (2/4), abnormal teeth (2/4)   Small hands/feet, high arched palate, wide interdental spaces                                                Delayed closure of the fontanels, delayed bone age, broad great toes, mild pectus carinatum
  Cardiac                                              Structural anomalies (6/8), arrhythmias (5/8)                                                                                                  Right ventricular hypertrophy (1/4)                                                                                                               ---                                                                                                          Pulmonary artery stenosis, atrial septal defect, prolonged QT interval
  Genital                                              Cryptorchidism (5/8), inguinal hernia (3/8)                                                                                                    ---                                                                                                                                               Hypoplastic scrotum                                                                                          ---
  Neurological                                         Truncal hypotonia (4/8), generalized hypertonia (1/8)                                                                                          Hypotonia (4/4), seizures (2/4)                                                                                                                   Truncal hypotonia, hypertonia of extremities, generalized epileptiform activity                              Truncal hypotonia, hypertonia of extremities
  Brain imaging                                        Cerebral atrophy or immature corpus callosum (3/8), enlarged ventricles (2/8)                                                                  Bilateral anophthalmia (3/4), microphthalmia (1/4)                                                                                                Enlarged ventricles, reduced periventricular volume, gliotic changes                                         Borderline normal ventricles
  Behavioural anomalies                                Fussy and irritable (1/8)                                                                                                                      Auto-aggressive behaviour (3/4), autistic features (2/4), mood-swings (1/4), hyperactivity (1/4)                                                  Hyperactivity, auto-aggressive behaviour, hand biting, autistic features                                     Self-hugging, repetitive hand movements

[^1]: These authors contributed equally to this work.
